At present, the price of Azvudine tablets for the treatment of new coronary pneumonia has been tentatively set, less than 300 yuan per bottle, 35 tablets per bottle, 1mg per tablet.
Since April 2020, Azvudine tablets have been approved for Phase III clinical trials at home and abroad.
On July 25 this year, Azvudine tablets obtained conditional approval from the China National Medical Products Administration, becoming the first domestically-made oral drug approved for marketing in China.
On August 2, the production ceremony of Azvudine tablets for new coronavirus pneumonia indications was held at Henan Real Biological Co., Ltd. in Pingdingshan City, Henan Province, officially announcing that Azvudine tablets were put into production.
(Fan Xiaoheng Chenghang)
Responsible editor: [Luo Pan]